(LYMD) Multi Units France - Lyxor - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: FR0010361683 • India Equity
LYMD: Exchange, Traded, Funds, India, Stocks
The Lyxor MSCI India UCITS ETF (Ticker: LYMD) is a Germany-domiciled exchange-traded fund designed to provide investors with exposure to the Indian equity market. Listed on the XETRA exchange, this ETF aims to replicate the performance of the Morningstar India Total Market Equity Index (TME) NR USD, which tracks the overall performance of Indian companies across various market capitalizations. The fund is managed by Lyxor, a subsidiary of Société Générale, and is structured as a UCITS-compliant ETF, adhering to European regulatory standards for transparency and investor protection.
As of the latest available data, the funds assets under management (AUM) stand at 677.41 million EUR, indicating a substantial investor base and liquidity in the market. The ETF is designed to appeal to investors seeking diversified exposure to Indias growth story, with a focus on large-, mid-, and small-cap companies. The Morningstar India TME NR USD index is a broad market index that includes equities listed on recognized exchanges in India, providing a comprehensive representation of the countrys equity market.
From a future outlook perspective, the Lyxor MSCI India UCITS ETF is positioned to benefit from Indias long-term structural growth drivers. As Aswath Damodaran would analyze, the funds prospects are closely tied to Indias demographic trends, digital transformation, and the potential for increased foreign investment. However, the fund is not without risks, including exposure to emerging market volatility, regulatory changes, and currency fluctuations. Investors should consider the funds tracking difference, expense ratio, and replication strategy when evaluating its suitability for their portfolios.
Additional Sources for LYMD ETF
LYMD ETF Overview
Market Cap in USD | 734m |
Category | India Equity |
TER | 0.85% |
IPO / Inception | 2006-11-07 |
LYMD ETF Ratings
Growth 5y | 65.8% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -25.5 |
Analysts | - |
Fair Price Momentum | 25.12 EUR |
Fair Price DCF | - |
LYMD Dividends
No Dividends PaidLYMD Growth Ratios
Growth Correlation 3m | -96.8% |
Growth Correlation 12m | -1.3% |
Growth Correlation 5y | 89.7% |
CAGR 5y | 15.85% |
CAGR/Max DD 5y | 0.77 |
Sharpe Ratio 12m | 0.96 |
Alpha | -10.67 |
Beta | 0.37 |
Volatility | 15.16% |
Current Volume | 16.9k |
Average Volume 20d | 32.6k |
As of March 15, 2025, the stock is trading at EUR 26.73 with a total of 16,940 shares traded.
Over the past week, the price has changed by -0.11%, over one month by -5.78%, over three months by -17.12% and over the past year by -5.06%.
Yes. Based on ValueRay Analyses, Multi Units France - Lyxor (XETRA:LYMD) is currently (March 2025) a good stock to buy. It has a ValueRay Growth Rating of 65.84 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LYMD as of March 2025 is 25.12. This means that LYMD is currently overvalued and has a potential downside of -6.02%.
Multi Units France - Lyxor has no consensus analysts rating.
According to ValueRays Forecast Model, LYMD Multi Units France - Lyxor will be worth about 27.6 in March 2026. The stock is currently trading at 26.73. This means that the stock has a potential upside of +3.22%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 27.6 | 3.2% |